Latest Breaking News On - Scott struthers - Page 4 : comparemela.com

Richard Scott Struthers Sells 40,951 Shares of Crinetics Pharmaceuticals, Inc (NASDAQ:CRNX) Stock

Richard Scott Struthers Sells 40,951 Shares of Crinetics Pharmaceuticals, Inc (NASDAQ:CRNX) Stock
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Robertw bairdRichard scott struthersFirst republic investment management incNews ratings for crinetics pharmaceuticals dailyInstitutional investors weigh in on crinetics pharmaceuticalsHermes incCrinetics pharmaceuticals incAlps advisors incCrinetics pharmaceuticals trading downCantor fitzgeraldGroup plcJefferies financial groupQuarter for crinetics pharmaceuticalsCrinetics pharmaceuticalsGet free reportScott struthers

Brokerages Set Crinetics Pharmaceuticals, Inc (NASDAQ:CRNX) Price Target at $54 17

Brokerages Set Crinetics Pharmaceuticals, Inc (NASDAQ:CRNX) Price Target at $54 17
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesMatthewk fustRichard scott struthersNews ratings for crinetics pharmaceuticals dailyCrinetics pharmaceuticalsAnalyst recommendations for crinetics pharmaceuticalsGoldman sachs group incCantor fitzgeraldSecurities exchange commissionVanguard group incFisher asset managementCrinetics pharmaceuticals company profileCrinetics pharmaceuticals incCrinetics pharmaceuticals stockInstitutional trading of crinetics pharmaceuticalsMorgan stanley

Crinetics Pharmaceuticals, Inc (NASDAQ:CRNX) Receives Average Recommendation of Moderate Buy from Analysts

Crinetics Pharmaceuticals, Inc (NASDAQ:CRNX) Receives Average Recommendation of Moderate Buy from Analysts
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Crinetics Pharmaceuticals, Inc (NASDAQ:CRNX) CEO Sells $2,013,560 67 in Stock

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) CEO Richard Scott Struthers sold 40,951 shares of the firm’s stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $49.17, for a total transaction of $2,013,560.67. Following the transaction, the chief executive officer now directly owns 237,835 shares in […]

New zealand generalNew zealandRobertw bairdRichard scott struthersCrinetics pharmaceuticalsCrinetics pharmaceuticals company profileWellington management groupNews ratings for crinetics pharmaceuticals dailyBlackrock incPricet rowe associates incVanguard group incSecurities exchange commissionCrinetics pharmaceuticals incInstitutional investors weigh in on crinetics pharmaceuticalsJennison associatesCrinetics pharmaceuticals stock down

Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome

Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

Scott struthersNatalie badilloCorey davisCrinetics pharmaceuticalsHead of corporate communicationsCrinetics pharmaceuticals incSecurities exchangePaltusotine treatment demonstrated rapidSustained reductionsFlushing episodesGenerally well toleratedPrior studiesConference call todayData review conference callSecurities actSecurities exchange act